Tzchentke T M, Schmidt W J
Grünenthal GmbH, Research and Development, Aachen, Germany.
Psychopharmacology (Berl). 2000 Apr;149(3):225-34. doi: 10.1007/s002130000379.
NMDA-receptor antagonists may be of potential therapeutic use in several states of disease. It has been reported that drugs like MK-801 can potentiate the rewarding effects of other drugs, which may complicate the therapeutic use of this class of drugs. However, since MK-801 appears to be an "atypical" drug in several respects, other NMDA-receptor antagonists may not share this effect of MK-801.
We tested the effects of memantine, a clinically used NMDA-receptor antagonist, in a paradigm that has previously shown the reward-potentiating effects of MK-801 to see if this drug would yield qualitatively comparable results.
The effects of memantine on morphine- and cocaine-induced potentiation of brain stimulation reward were examined, using the rate-free curve-shift paradigm.
Low doses of morphine (2.5 mg/kg) and cocaine (5 mg/kg) produced moderate decreases in the reward threshold frequency reflected in moderate leftward shifts of the function relating response rate to stimulation frequency. These effects were not altered by co-administration of an intermediate dose of memantine (5 mg/kg), but maximum response rate was significantly increased by these drug combinations. Higher doses of morphine (7.5 mg/kg) and cocaine (10 mg/kg) had stronger effects on the rate-frequency function and reward threshold. These effects were enhanced by co-administration of a high dose of memantine (10 mg/kg), while the effects on maximum response rate were less pronounced.
These results demonstrate that fairly high doses of memantine and morphine or cocaine have to be combined in order to observe an enhancement of the latter drugs' potentiation of brain stimulation reward. In this respect, memantine differs markedly from MK-801, another non-competitive NMDA-receptor antagonist which has been shown to interact with morphine and cocaine at very low doses.
N-甲基-D-天冬氨酸(NMDA)受体拮抗剂在多种疾病状态下可能具有潜在的治疗用途。据报道,像MK-801这类药物可增强其他药物的奖赏效应,这可能会使此类药物的治疗应用复杂化。然而,由于MK-801在多个方面似乎是一种“非典型”药物,其他NMDA受体拮抗剂可能不会有MK-801的这种效应。
我们在先前已显示MK-801具有奖赏增强效应的范式中测试了临床使用的NMDA受体拮抗剂美金刚的效应,以观察该药物是否会产生定性可比的结果。
使用无速率曲线位移范式,研究了美金刚对吗啡和可卡因诱导的脑刺激奖赏增强作用的影响。
低剂量的吗啡(2.5毫克/千克)和可卡因(5毫克/千克)使奖赏阈值频率适度降低,表现为反应速率与刺激频率关系函数适度向左移位。联合给予中等剂量的美金刚(5毫克/千克)不会改变这些效应,但这些药物组合会使最大反应速率显著增加。较高剂量的吗啡(7.5毫克/千克)和可卡因(10毫克/千克)对速率-频率函数和奖赏阈值有更强的作用。联合给予高剂量的美金刚(10毫克/千克)可增强这些效应,而对最大反应速率的影响则不太明显。
这些结果表明,必须将相当高剂量的美金刚与吗啡或可卡因联合使用,才能观察到后者对脑刺激奖赏增强作用的增强。在这方面,美金刚与另一种非竞争性NMDA受体拮抗剂MK-801明显不同,后者已被证明在极低剂量下就能与吗啡和可卡因相互作用。